| pubmed-article:16632360 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16632360 | lifeskim:mentions | umls-concept:C0259969 | lld:lifeskim |
| pubmed-article:16632360 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:16632360 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:16632360 | lifeskim:mentions | umls-concept:C1689847 | lld:lifeskim |
| pubmed-article:16632360 | lifeskim:mentions | umls-concept:C1690469 | lld:lifeskim |
| pubmed-article:16632360 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:16632360 | pubmed:dateCreated | 2006-5-8 | lld:pubmed |
| pubmed-article:16632360 | pubmed:abstractText | Analogues of the tetrahydroisoquinoline family of antitumor antibiotics, 3-epi-jorumycin (3) and 3-epi-renieramycin G (4), in addition to their respective parent natural products (-)-jorumycin (1) and (-)-renieramycin G (2) were evaluated against both human colon (HCT-116) and human lung (A549) cancer cell lines. (-)-Jorumycin (1) displayed potent growth inhibition with GI50 values in the low nanomolar range (1.9-24.3 nM), while compounds 2-4 were found to be substantially less cytotoxic (GI50 0.6-14.0 microM). | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16632360 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16632360 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16632360 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16632360 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:16632360 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:16632360 | pubmed:author | pubmed-author:WilliamsRober... | lld:pubmed |
| pubmed-article:16632360 | pubmed:author | pubmed-author:SpencerJeffre... | lld:pubmed |
| pubmed-article:16632360 | pubmed:author | pubmed-author:LaneJonathan... | lld:pubmed |
| pubmed-article:16632360 | pubmed:author | pubmed-author:MortaraKyleK | lld:pubmed |
| pubmed-article:16632360 | pubmed:author | pubmed-author:EstevezAlbert... | lld:pubmed |
| pubmed-article:16632360 | pubmed:author | pubmed-author:CallanOndineO | lld:pubmed |
| pubmed-article:16632360 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16632360 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:16632360 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16632360 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16632360 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16632360 | pubmed:pagination | 3180-3 | lld:pubmed |
| pubmed-article:16632360 | pubmed:dateRevised | 2011-9-26 | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:meshHeading | pubmed-meshheading:16632360... | lld:pubmed |
| pubmed-article:16632360 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16632360 | pubmed:articleTitle | Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G. | lld:pubmed |
| pubmed-article:16632360 | pubmed:affiliation | Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA. | lld:pubmed |
| pubmed-article:16632360 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16632360 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:16632360 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16632360 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16632360 | lld:pubmed |
